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Purpose: Leber congenital amaurosis (LCA) is one of the most severe inherited retinal dystrophies with the earliest age
of onset. Mutations in the Crumbs homologue 1 (CRB1; OMIM 600105) gene explain 10%–24% of cases with LCA
depending on the population. The aim of the present work was to study a fetal mutation associated to LCA in maternal
plasma by a new methodology in the noninvasive prenatal diagnosis field: the denaturing High Performance Liquid
Chromatography (dHPLC).
Methods: This study presents the case of a compound heterozygous fetus for two mutations in CRB1 (1q3.1-q32.2).
dHPLC and automated DNA sequencing were used to detect the paternally inherited fetal mutation in a maternal plasma
sample collected at the 12th week of gestation. To test the detection limit of dHPLC, we made serial dilutions of paternal
DNA in control DNA.
Results: We were able to detect the presence of the paternally inherited fetal CRB1 mutation in maternal plasma by
dHPLC. Moreover, by comparing chromatograms of serial dilutions to the plasma sample, we could ascertain that the
percentage of fetal DNA in maternal plasma was at least 2%. However, the detection of the fetal mutation was not possible
by automated DNA sequencing.
Conclusions: dHPLC seems to be sensitive enough to detect small amounts of fetal DNA in maternal plasma samples. It
could be a useful tool for the noninvasive prenatal detection of paternally inherited point mutations associated with
retinopathies.
Leber congenital amaurosis (LCA; OMIM 204000) is a
severe form of inherited retinal dystrophy with the earliest
onset  [1-6].  LCA  is  generally  inherited  in  an  autosomal
recessive manner although some autosomal dominant families
have been described [7-9]. Nonsyndromic LCA has so far
been associated with mutations in 12 genes (RetNet).
Mutations  in  Crumbs  homologue  1  (CRB1;  OMIM
600105) have been associated with several visual disorders
including retinitis pigmentosa (RP) with [10,11] or without
[11,12] preserved para-arteriolar retinal pigment epithelium,
paravenous pigmented chorioretinal atrophy [13], and LCA
[14,15]. Of these disorders, LCA is the most severe form of
inherited  retinal  dystrophy  and  is  characterized  by  severe
visual impairment from birth or very early in infancy and a
decreased or absent electroretinogram (ERG) response [16].
Mutations in CRB1 explain 10%–24% of cases with LCA
depending on the population [4-9,17-21].
The first evidence of the existence of fetal material in
maternal tissue was discovered in 1893. Fetal cells were found
in the lungs of pregnant women who died of eclampsia [22].
But it was in the 1980s when this discovery was taken into
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consideration,  opening  the  possibility  to  develop  a
noninvasive prenatal diagnosis (NIPD) to avoid the risk that
obstetric invasive techniques entail. Fetal sex assessment and
the study of the most common aneuploidies were the first
diagnoses  carried  out  from  the  analysis  of  fetal  cells  in
maternal blood [23,24]. In 1997, Lo et al. [25] discovered the
existence of circulating cell free fetal DNA (ccffDNA) in
maternal blood. This discovery was based on the detection of
Y-chromosome specific sequences in the maternal circulation
of pregnant women bearing a male fetus. Once the presence
of  this  fetal  DNA  in  maternal  plasma  was  widely
demonstrated  [26-28],  some  studies  focused  on  the
quantification  of  this  fetal  material  [29-31].These  studies
reported that the ccffDNA represented around 3%–6% of the
total DNA present in the maternal plasma [29]. In addition, it
was  observed  that  the  amount  of  ccffDNA  increases
throughout gestation [31] and disappears immediately after
delivery [32].
An important limitation of these kinds of studies is that,
because  of  the  presence  of  maternal  DNA  in  the  plasma
samples, they are bound solely to the detection of paternally
inherited fetal sequences. Therefore, the ccffDNA present in
maternal  plasma  has  been  mainly  used  for  fetal  gender
assessment [26-28], determination of fetal rhesus status in Rh-
negative pregnant women [33-35], and detection of paternally
inherited disorders [36-41].
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1388Because of the low percentage of ccffDNA present in
maternal  plasma,  all  studies  require  the  use  of  sensitive
technologies. Real-time PCR (RT-PCR) has been the most
widely used technique for this aim because its high sensitivity
enables  the  detection  of  small  amounts  of  target  DNA
sequences [28,42-44]. However, other approaches, such as
restriction analysis [37] or quantitative fluorescent PCR (QF-
PCR)  [45,46],  have  been  also  used.  In  addition  to  these
techniques, our group described in a previous report the use
of  automated  DNA  sequencing  for  the  detection  of  a
paternally  inherited  fetal  mutation  associated  with  an  X-
linked RP [41].
Here, we present the first evidence of the application of
denaturing  high  performance  liquid  chromatography
(dHPLC)  for  the  detection  of  an  LCA-associated  fetal
mutation in maternal plasma. dHPLC is a technique currently
used  in  diagnostic  laboratories  for  the  detection  of  point
mutations or small deletions/insertions. However, to the best
of our knowledge, this technology has not been applied in the
NIPD field yet. The aim of this work is to report the use of
this technique for the detection of a paternally inherited fetal
mutation associated to LCA in maternal plasma in the first
trimester of gestation.
METHODS
Patients: In the present study, the patient was an in utero fetus.
The parents of the fetus came to our clinic to undergo a chorion
biopsy for prenatal diagnosis. The parents were heterozygous
for two different mutations in CRB1: the father carried the
p.Cys896ter  mutation  in  exon  8  and  the  mother  the
p.Cys948Tyr mutation in exon 9 (Figure 1).
Sample collection: Maternal blood (9 ml) was collected in
EDTA tubes at the 12th week of gestation before the chorion
biopsy  was  performed.  This  collection  was  done  under
informed consent and according to the Helsinki declaration.
The sample was centrifuged at 1,600x g for 10 min. Plasma
was collected in 1 ml fractions and centrifuged at 16,000x g
for 10 min to eliminate all maternal cells present in the plasma
sample. Supernatant was collected in new tubes and stored at
–20 °C.
In the present study, chorion villi sample was used as fetal
control,  paternal  DNA  served  as  positive  control  for  the
p.Cys896ter mutation and maternal DNA was used as wild-
type control for the p.Cys896ter mutation.
DNA extraction: DNA was extracted from 2 ml of maternal
plasma  with  the  QIAmp  DNA  Blood  MiniKit  (Qiagen,
Hilden, Germany) following the protocol recommended by
the  manufacturer  with  one  modification:  the  eluate  was
reloaded into the column and centrifuged again. The parental
DNAs were already available from previous studies. DNA
extraction from the chorion villi sample was performed using
the  Tissue  Extraction  Kit  in  the  BioRobot  EZ1  (Qiagen)
following the recommended protocol.
Polymerase chain reaction amplification: CRB1 is composed
of 12 exons. The mutation carried by the father was in exon 8
(p.Cys896ter). A 276 bp fragment of exon 8 was amplified by
PCR.  Amplification  was  performed  using  25  μl  of  DNA
extracted from the plasma sample as a template. For controls
(paternal DNA, maternal DNA, and chorion biopsy DNA), 2
ng of DNA were used as PCR control templates. The final
volume  of  the  reaction  was  50  μl  containing:  5  pmol  of
CRB1ex8 forward, 5′-CAA CAT TTT TCT ATT TAG TTG
CC-3′  (Applied  Biosystems,  Foster  City,  CA);  5  pmol  of
CRB1ex8 reverse, 5′-CTC AAA TGT CGC AAC TTA ACT
G-3′  (Applied  Biosystems);  1X  PCR  buffer  with  2.5  nM
MgCl2  (Roche,  Indianapolis,  IN);  200  μM  each
deoxynucleotide; and 1U of FastStart Taq DNA Polymerase
(Roche). Amplification was performed in a GeneAmp PCR
System 2700 thermal cycler (Applied Biosystems). After an
initial incubation of 95 °C for 10 min, the reaction was cycled
for 30 s at 95 °C, 20 s at 60 °C, and 50 s at 74 °C for 40 cycles,
followed by a final extension of 5 min at 74 °C. PCR products
were  analyzed  by  two  different  methods:  dHPLC  and
automated sequencing.
Denaturing high performance liquid chromatography: In this
technique, the PCR products are denatured and subsequently
Figure 1. Genealogy of the family. Parents were carriers of a different
mutation in CRB1 (paternal mutation in red color). Haplotypes for
four markers flanking the gene are showed (color bars). The first
child (VI1) was affected with LCA. The probandus of the present
study (VI:2) was carrier of both parental mutations.
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1389subjected to a slow renaturalization. During renaturalization,
complementary  sequences  perfectly  reanneal,  creating
homoduplex  forms.  However,  the  presence  of  a  different
nucleotide in a specific position in one of the strands of DNA
will generate mismatched double-stranded DNA fragments
called  heteroduplexes.  dHPLC  can  reveal  the  presence  of
differences in the sequences based on the detection of the
heteroduplex forms.
Denaturing of the PCR products was performed at 95 °C
for  5  min,  and  posterior  renaturing  was  done  at  room
temperature for over 1 h. dHPLC analysis was performed
using  a  WAVETM  DNA  fragment  Analysis  System
(Transgenomic  Inc.,  Omaha,  NE).  Subsequently,  5  μl  of
renatured  products  were  loaded  on  a  C18  reversed-phase
column  (DNASepTM  column;  Transgenomic  Inc.)  and
analyzed  with  an  acetonitrile  gradient  formed  by  mixing
buffers A and B (WAVE OptimizedTM; Transgenomic Inc.).
The optimal partial denaturing temperature used was 59.9 °C,
which was calculated by the WAVE Maker program (Ver. 4.1;
Transgenomic Inc.).
In order to know the detection limit of the dHPLC for the
p.Cys896ter mutation, a battery of serial dilutions of paternal
DNA (carrier control) in maternal DNA (wild-type DNA) was
made.  These  dilutions  were  made  with  different  ratios  of
paternal DNA/maternal DNA (% of paternal DNA): 50/50
(50%), 25/75 (25%), 15/85 (15%), 10/90 (10%), 5/95 (5%),
4/96 (4%), 3/97 (3%), 2/98 (2%), and 1/99 (1%).
Automated  sequencing:  PCR  products  were  purified  by
QIAGEN  Purification  Kit  columns  (Qiagen).  The  plasma
sample was eluted in 30 µl of elution buffer and the controls
in 50 µl. Based on the manufacturer’s recommendations, the
sequencing  reaction  was  performed  in  a  final  volume  of
20 μl containing 5 μl of purified PCR product for the controls
and 10 μl for the plasma sample, 10 pmol of CRB1ex8 forward
or  reverse  primer,  and  dRhodamine  terminator  cycle
sequencing  ready  reaction  kit  (Applied  Bioscience).  The
product was electrophoresed in an ABI Prism 3100 Genetic
Analyzer  (Applied  Bioscience)  and  analyzed  with  the
Sequencing  Analysis  5.1.1  software  package  (Applied
Bioscience).
RESULTS
Denaturing  high  performance  liquid  chromatography
analysis: dHPLC analysis of the control DNA for the mutation
in  exon  8  (maternal  DNA)  and  the  heterozygous  mutant
control  (paternal  DNA)  revealed  two  different  and
distinguishable  chromatograms.  The  control  DNA
chromatogram  showed  a  unique  peak  generated  by  the
homoduplex  forms.  However,  the  heterozygous  mutant
control presented a different pattern comprised three peaks:
one peak corresponding to the homoduplexes, and two smaller
additional  peaks  corresponding  to  the  heteroduplex  forms
(Figure 2).
Chromatograms from the serial dilutions showed how the
two  peaks  corresponding  to  the  heteroduplex  forms
diminished  as  the  amount  of  paternal  DNA  in  the  mix
decreased. In mixes with low concentrations of paternal DNA,
these two peaks became a “slight peak” which was visible
until the 2/98 (2%) dilution. When the mutation was in a
percentage lower than 2% it was not detectable because the
chromatogram was similar to the one showed by the maternal
DNA. (Figure 3)
Analysis of the plasma sample showed a chromatogram
in which the ‘slight peak’, previously observed in the 5% and
2%  dilution  controls  and  associated  to  the  mutation,  was
present (Figure 4). The presence of this slight peak in the
maternal  plasma  sample  chromatogram  represented  the
presence of the paternally inherited fetal mutation.
The analysis of the chorion biopsy revealed that the fetus
had inherited the paternal mutation.
Sequencing analysis: The detection of the paternal mutation
(p.Cys896ter) was determined by the presence of an adenine
(instead of a thymine) at the mutation site (c.2688 T>A). We
were not able to detect the paternal mutation in the plasma
sample by automated sequencing. However, the mutation was
observed in the analysis of the chorion villi sample.
DISCUSSION
Different techniques have been applied to detect fetal DNA in
maternal plasma. The tools most commonly used are RT–
PCR,  QF-PCR,  and  restriction  analysis.  However,  the
adoption of new emerging techniques, usually more sensitive,
Figure 2. Chromatograms of the control DNAs obtained by dHPLC.
After PCR amplification of exon 8 of CRB1 (where the p.Cys896ter
mutation is located), the PCR products were analyzed by dHPLC.
A: Electropherogram showed by the paternal DNA (carrier for the
p.Cys896ter  mutation).  1:  Double-peak  generated  by  the
heteroduplexes forms associated to the presence of the p.Cys896ter
mutation in the sample. 2: Peak generated by the homoduplexes. The
presence  of  both  homo  and  heteroduplexes  peaks  indicates  a
heterozygous  genotype  for  the  p.Cys896ter  mutation.  B:
Electropherogram showed by the maternal DNA (wild-type for the
p.Cys896ter mutation). 2: Peak generated by the homoduplexes. The
only  presence  of  homoduplexes  peak  represents  a  wild-type
genotype.
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noninvasive prenatal diagnosis.
In  the  present  study,  the  parents  of  the  fetus  were
heterozygous for a different mutation in different exons of
CRB1.
The  aim  of  this  work  was  to  introduce  the  dHPLC
technology for the detection of a paternally inherited fetal
mutation associated to LCA in maternal plasma in the first
Figure  3.  Chromatograms  showed  by  the  analysis  of  the  serial
dilutions by the dHPLC. The percentage data indicate the amount of
the  carrier  DNA  present  in  the  dilution.  The  double-peak
corresponding  to  the  heteroduplexes  decreases  in  size  as  the
percentage of mutant DNA in the sample gets lower. From the 5%
to the 2% dilution, the double-peak becomes a slight peak (pointed
by the arrows in the figure). Below the 2%, the heteroduplexes could
not  be  distinguished.  These  chromatograms  revealed  that  the
mutation was detectable up to the 2% dilution.
Figure 4. Analysis of the maternal plasma sample by dHPLC. A:
Chromatograms from the maternal plasma sample (black graph) and
the wild-type control DNA chromatogram (pink graph). They are
shown overlapped in order to be compared. The arrow points the peak
shape in the graph associated to the presence of the p.Cys896ter
mutation in the maternal plasma sample and not present in the wild-
type chromatogram; B: Enlarge image from the region of interest
revealing  the  carrier  condition  of  the  fetus  for  the  p.Cys896ter
mutation.
trimester of gestation. Exclusion of the paternal mutation in
the maternal plasma would indicate that the fetus was, at
worst,  a  carrier  of  the  maternal  mutation.  Therefore,
conventional invasive procedures could be avoided.
Used as a screening tool, the dHPLC technique searches
for  unknown  mutations  in  large  scale  studies  or  known
mutations  in  new  patients  with  a  previously  diagnosed
relative. Some advantages of this tool are its easy handling,
its  ability  to  rapidly  process  samples,  and  its  low  cost.
Moreover, it has shown excellent results in clinical practice
[47].
Considering  the  low  percentage  of  ccffDNA  in  the
maternal plasma previously reported [29] and in order to know
the detection limit of the dHPLC for the p.Cys896ter mutation,
serial dilutions of paternal DNA (carrier for the mutation)
were  made.  In  addition,  the  comparison  of  the  migration
patterns between the serial dilutions and the plasma sample
was the strategy followed to determine the genotype of the
fetus for the paternal mutation.
Analysis of the chromatograms from the dilutions helped
to  establish  the  detection  limit  of  the  technique  for  the
p.Cys896ter mutation as 2% of carrier DNA present in the
sample. This high level of detection made us look at this
technique as a promising tool for the detection of fetal DNA
in maternal blood. This hypothesis was confirmed when we
were able to detect the mutation by analyzing the maternal
plasma sample.
The correspondence of the migration patterns of the serial
dilutions (5% and 2% dilutions) with the one showed by the
plasma sample let us ascertain the carrier condition of the fetus
for  the  paternal  mutation.  Besides,  this  assay  design  also
allowed  us  to  speculate  that  the  amount  of  fetal  DNA
represented around 2% to 5% of the total DNA present in the
plasma sample analyzed.
In  a  previous  paper,  we  reported  the  detection,  by
automated sequencing, of a fetal mutation associated to a X-
linked Retinitis Pigmentosa in maternal plasma collected at
the 19th week of gestation [41]. However, a sample collected
from the same pregnancy at the 10th week was also analyzed
but the mutation was not detected [41]. In the present study,
the paternally inherited fetal mutation has been detected in the
maternal plasma (at the 12th week) by the dHPLC method but
not  by  automated  sequencing.  Therefore  both  studies,  in
which automated sequencing has been used, are concordant
about  the  inefficiency  of  the  technique  for  detection  of
ccffDNA in maternal plasma samples in the first trimester of
gestation. This fact would be in accordance with previous
reports about the scarcity of ccffDNA in the first trimester of
gestation [30,31].
This work opens up the possibility to incorporate the
dHPLC technique for the study of paternally inherited fetal
mutations in maternal plasma. It has shown to be sensitive
enough to detect ccffDNA in the first trimester of gestation.
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1391However the automated sequencing technique has not been
efficient for the detection of ccffDNA at this early stage of
gestation.  The  creation  of  serial  dilutions  containing  low
percentages of paternal DNA has shown to be an essential
strategy for the analysis of paternally inherited fetal mutations
in maternal plasma by dHPLC. Considering that the detection
limit of the technique could be variable for the analysis of
different mutations, further studies are required to evaluate the
accuracy of the method for other mutational changes.
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